Morphosys Signs $818M Celgene Deal for MOR202
By Cormac Sheridan
Thursday, June 27, 2013
Shares in Morphosys AG surged by more than 17 percent during trading Thursday morning on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.